Tg Therapeutics TGTX

$54.17 +1.01 (1.90%)

Valuation

Market cap
8,137,148,000
Revenue TTM
$616,290,000
Net income TTM
$447,180,000
PE ratio
19.07
Forward PE
58.04
Profit margin
72.56%
Debt to equity
1.23

Trading

Volume
1,978,000
Avg volume
1,755,680
Day's range
$51.83 – $55.81
Shares out
153,069,000
Stochastic %K
47%
Beta
1.80
Analysts
Strong Sell
Price target
$64.38

Price

Company profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsin...

Show more

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Industry
Biotechnology
Sector
Healthcare
Phone
212 554 4484
Website
https://www.tgtherapeutics.com
Address
3020 Carrington Mill Blvd., Suite 475, Morrisville, United States

Latest news

Stocktwits

SteveTexans Oct 24, 2:25 AM
$TGTX Below posted Gemini results. Is feasible. ChatGPT and Copilot you don’t even want to know their numbers. This is Grok. https://grok.com/share/bGVnYWN5_7ab292f6-3454-4ea2-b24b-0e6ed3ce246a Take away for Bull Case. Very optimistic. Bull / acquisition scenario: • Strategic buyer pays 40–60% premium on current price for the commercial asset + SC optionality → $75–90+ upfront. • CVR of $10–25+/share (or equivalent total) tied to SC approval/launch sales hurdles and/or azer-cel progress is realistic to close any gap. Total potential consideration could reach $90–110+ in optimistic cases if SC data are strong and azer-cel shows clear efficacy signal. • Buyer synergy: larger MS franchise (Biogen), autoimmune expansion, or manufacturing/commercial leverage.
0 replies
Atomickb Oct 24, 2:15 AM
$TGTX - Thats it . The short thesis is about the competition not bizarocel which will take 6 8 years to grt somewhere if at all. Now the shorts would need to cover. The buyout can hapen now that novartis results are weak. Sign that darn deal at 100 and be done with MW. Get into the bp and then do experimental work wirh bizarocell to your hearts content . Or retirea. Or manage that POS FBIO
1 replies
cjp0608 Oct 24, 1:37 AM
$TGTX Novartis dropped our entire market cap today with poor btk results. Make it make sense 😂
0 replies
SteveTexans Oct 24, 12:45 AM
$TGTX https://share.gemini.google/K309JxitxgbW Bottom line deal TGTX probably would accept. As of today.
1 replies
stocky1234 Oct 23, 11:26 PM
$TGTX surely the tight cunts are queing up
0 replies
cjp0608 Oct 23, 11:22 PM
$TGTX it’s comical that the move up today was from poor BTK data vs our azer cell data. Viable azer cell product moving into phase 2 is apparently worth nothing 😂 on to earnings
1 replies
TroyTiger Oct 23, 11:16 PM
$TGTX Nov Call Options had some good volumes today.. Bullish..
0 replies
OlDocAngus Oct 23, 10:31 PM
$TGTX https://modernity.news/2026/10/22/im-sorry-but-this-is-funny-2/
0 replies